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Voltage-gated calcium channels (VGCCs) mediate calcium entry into excitable cells in response to membrane depolarization. During the past
decade, our understanding of the gating and functions of VGCCs has been illuminated by the analysis of mutations linked to a heterogeneous
group of genetic diseases called “calcium channelopathies”. Calcium channelopathies include muscular, neurological, cardiac and vision
syndromes. Recent data suggest that calcium channelopathies result not only from electrophysiological defects but also from altered α1/CaV
subunit protein processing, including folding, posttranslational modifications, quality control and trafficking abnormalities. Overall, functional
analyses of VGCC mutations provide a more comprehensive view of the corresponding human disorders and offer important new insights into
VGCC function. Ultimately, the understanding of these pathogenic channel mutations should lead to improved treatments of such hereditary
diseases in humans.
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channelopathies
In excitable cells, the membrane potential serves as the
primary integrator of numerous ionic channel inputs. In that
context, voltage-gated calcium channels (VGCCs) provide a
unique route for calcium entry, thereby controlling a wide
variety of physiological processes, such as excitation–contrac-
tion coupling, neurotransmitter release, hormone secretion and
gene expression. Fig. 1 illustrates the overall functional and
molecular properties of VGCCs (for review [1]). According to
their threshold of activation, VGCCs are categorized as low
voltage-activated (LVA) and high voltage-activated (HVA).
Based on biophysical and pharmacological features, VGCCs are
designated as T-, L-, N-, P/Q- and R-types. VGCCs are
composed of a pore forming α1/CaV subunit, which is
associated – in the case of L-, N-, P/Q- and R-types channels –
with regulatory α2δ, β and γ subunits (Fig. 1). Ten genes
(named CACNA1A-I and CACNA1S, see Fig. 2) are coding for
the α1/CaV subunits [2]. Alternative splicing largely enhances⁎ Corresponding author. Tel.: +33 499 619 939; fax: +33 499 619 901.
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doi:10.1016/j.bbamcr.2006.08.049the number of active forms of the α1/CaV proteins (reviewed in
[3]). Overall, the bulk of studies performed in the 1990s has
greatly contributed to the identification of the key mechanisms
that generate multiple forms of VGCC activity (reviewed in
[1,4]).
Over the past decade, several inherited disorders in humans
have been linked to mutations in the genes encoding VGCCs.
These genetic diseases are designated “calcium channelopa-
thies”. There are various kinds of disorders, essentially
muscular and neurological that involve many of the VGCC
genes. Always when considering a channelopathy, an electro-
physiological alteration is suspected as a primary cause of the
disease. However, emerging evidence indicates that several
different aspects of VGCC processing and function can be
affected. Here we present the various calcium channelopathies
identified to date and discuss the current knowledge regarding
the pathogenicity of the corresponding mutations.
2. Calcium channelopathies associated with L-type VGCCs
Four genes encode L-type VGCCs (Fig. 2) and their
expression is either restricted in specialized tissues, as for
CaV1.1 (CACNA1S) and CaV1.4 (CACNA1F) in skeletal
Fig. 1. (A) Macroscopic calcium current (ICa) is activated by membrane
depolarization from a negative resting/holding membrane potential. At rest,
voltage-gated calcium channels (VGCCs) are in the close state (1). Upon
depolarization, these channels move to open state (2), which corresponds to ICa
activation. When depolarization is maintained, the ICa amplitude decreases as
VGCCs switch to the inactivated state (3). (B) A cartoon representing the
oligomeric structure of VGCCs. High voltage-activated (HVA) VGCCs
comprise both the pore forming subunit, α1, and the auxiliary/regulatory
subunits, α2/δ, β and γ. The oligomeric structure of low voltage-activated (LVA/
T-type) VGCCs is yet unknown. (C) The pore-forming subunit, α1, now named
CaV subunit, comprises both the voltage-sensor (positively charged S4
segments, in blue) and the pore region (in red).
Fig. 2. A schematic phylogenetic tree illustrating the various VGCCs
subfamilies. Four genes encode the L-type VGCCs. Three genes encode the
neuronal P/Q- N- and R-types. Three genes also code for the T-type VGCCs.
Note that all these genes have been localized on human chromosome (see right
column) and that detailed information can be found on the OMIM and HUGO/
GDB web sites.
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for CaV1.2 (CACNA1C). The first calcium channelopathy
described in humans was the hypokalemic periodic paralysis
type 1, linked to mutations in the CACNA1S gene (HypoPP1 or
HOKPP1, OMIM #170400) that is specifically expressed in
skeletal muscle. Missense mutations of arginine residues within
the S4 voltage sensor segment (see Fig. 1) of domains II and IV
were identified [5,6]. In heterologous expression systems, thesemutations result in a reduced calcium current density [7] and
only mild changes in the gating properties [8]. At the present
time, the precise functional consequences of the HypoPP1
mutations of the CaV1.1 subunit remain unknown. It is
proposed that a reduced calcium channel activity might impair
ATP-sensitive potassium channels, since these channels are
affected in muscle of HypoPP1 patients [9]. Interestingly,
another mutation within CACNA1S was linked to malignant
hyperthermia susceptibility type 5 (MHS5, OMIM #601887).
This mutation results in an amino-acid substitution (R1086H)
within the intracellular III–IV linker [10], suggesting that this
region of the CaV1.1 subunit interacts with the ryanodine
receptor (RyR1). Indeed, heterologous expression experiments
have revealed that this MHS5 mutation of CaV1.1 enhances
calcium release in skeletal muscle cells [11].
Genetic linkage analysis of incomplete X-linked congenital
stationary night blindness type 2 (CSNB2, OMIM #300071), a
recessive non-progressive retinal disorder, identified many
mutations within a novel calcium channel gene: CACNA1F.
This gene encodes a pore-channel protein, CaV1.4/α1F, that
shares strong homology with other dihydropyridine-sensitive
(L-type) calcium channel CaV1 proteins. Over sixty CSNB2
mutations have been identified to date in CACNA1F, including
ten in splice acceptor and donor sites. Half of the CACNA1F
mutations in the coding region are nonsense and frameshift
mutations that are predicted to cause protein truncation and
loss of channel function ([12], reviewed in [13]). The other
CACNA1F mutations are missense mutations, theoretically
leading to functional channels [14]. However, various altera-
tions have been reported in CaV1.4 channels expressing these
missense mutations. Some cause an apparent reduction in
current density [15], while some others result in no significant
reduced expression at the protein level but display altered
channel activity [14,16]. Yet others express as well as the wild
type channel and display unchanged macroscopic current
properties, suggesting that this later set of CaV1.4 mutants may
be pathogenic via a different mechanism. Of interest, Hoda
Fig. 3. Human (A) and mouse spontaneous mutations (B) in the CaV2.1/α1
subunit of the P/Q-type calcium channel. (A) This schematic secondary structure
diagram indicates the location of many (but not all) mutations FHM1 (●), EA2
(◯) and SCA6 [CAG] mutations. Mutations that lead to intermediate
phenotypes, as progressive ataxia (⋄), progressive ataxia with hemiplegic
migraine (♦) and episodic and progressive ataxia with absence epilepsy (▪) are
mentioned. (B) Schematic representation of the putative P/Q-type calcium
channel structure in mouse, based on the identified mutations in the α1A/CaV2.1,
α2/δ2, β4 and γ2 subunits (see Table 1 for the mutations symbols).
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expression level of the L1364H mutant channels was reduced
when functional expression is achieved at physiological
temperature, while no such difference is observed when
mammalian cells were cultivated at 30 °C, or in Xenopus
oocytes. These observations indicate that CSNB2 symptoms
might not exclusively result from loss of CaV1.4 channel
activity or gating changes (reviewed in [13]) but in some cases
could result from a decrease in CaV1.4 expression at
physiological temperature. In light of these data, it is worth
considering that some missense mutations affecting CaV1.4
channels could result in altered protein folding and trafficking.
Interestingly, another recessive retinal disease, the X-linked
cone-rod dystrophy type 3 (CORDX3, OMIM #300476) that
share some clinical features with CSNB2, was recently linked to
a mutation in CACNA1F leading to altered splicing [17]. It is
predicted that this mutation results in non-functional CaV1.4
channels.
Mutations in CACNA1C gene, which codes for the CaV1.2
subunit – the so-called cardiac calcium channel – have been
recently linked to a complex disease named Timothy syndrome
(TS, OMIM #601005). TS is a rare childhood multiorgan
disorder characterized especially by severe electrophysiological
cardiac defects and sudden death. Other prominent features
include syndactyly, immune deficiency, intermittent hypogly-
cemia, cognitive abnormalities and autism. TS appears as a
sporadic trait in all but one family [18,19] and, therefore, is
linked to de novo missense mutation in exon 8A of the CaV1.2
subunit of L-type channels. The first de novomissense mutation
identified was a G406R substitution occurring in exon 8A of
CACNA1C [18]. Two additional mutations arising in exon 8:
G402S and G406R, which lead to slightly different clinical
features, were subsequently described [19]. The alternatively
spliced exon 8 and 8A code for the S6 segment of domain I,
exon 8 being the dominant splice variant in the heart and brain.
Both TS mutations cause nearly complete failure of L-type
calcium channel inactivation in heterologous expression
systems, resulting in maintained inward calcium currents during
depolarization. Therefore, TS CaV1.2 mutations can be depicted
as gain of function mutations. Many of the phenotypic
abnormalities in TS are likely to be related to an enhanced
calcium entry due to the lack of channel inactivation. For
instance, absence of L-type channel inactivation is predicted to
delay action potential repolarization and consequently to favour
long QT syndrome (LQT8), which is observed in TS [18]. In
contrast, very little is known regarding the molecular mechan-
isms of autism spectrum disorders (ASD). These data, as well as
the recent identification of T-type channel (CaV3.2) mutations
linked to ASD (see below), suggest that aberrant calcium
signalling linked to mutations in VGCCs may contribute to
ASD.
3. Calcium channelopathies associated with neuronal
P/Q-type VGCCs
While the most common migraine, seizure and ataxia
syndromes correspond to complex multigenic syndromes,several monogenic forms of these diseases involving the gene
CACNA1A have been characterized (Fig. 2). CACNA1A
encodes alternate splice isoforms of the CaV2.1 subunit that
generate the P- and Q-type channels, respectively [20]. P/Q type
channels are almost exclusively expressed in neuronal and
neuroendocrine cells. They are preferentially located at
presynaptic terminals where they play a central role in
neurotransmitter release, especially excitatory neurotransmit-
ters, as well as at somatodendritic membranes, where they
contribute to neuronal excitability (reviewed in [21]). Among
the three genes that code for the so-called “neuronal” VGCCs
(or CaV2): N-, P/Q- and R-types (Fig. 2), only mutations in
CACNA1A have been identified to date. Mutations linked to
familial hemiplegic migraine type 1 (FHM1) and episodic
ataxia type 2 (EA2) were described originally by Ophoff et al.
[22]. This was further documented and expanded by many
groups (for a recent review, see [23]). In the meantime, a
polymorphic CAG repeat was described in the human
CACNA1A gene [24] providing a molecular basis for
spinocerebellar ataxia type 6 (SCA6). These allelic CaV2.1
disorders (Figs. 2 and 3) have been extensively studied in recent
years (for review, see [23]).
Fig. 4. Mutations in calcium channelopathies possibly affect any of the cellular
pathways involved in the VGCC biogenesis and trafficking to the plasma
membrane: a working hypothesis. Altered VGCC function may arise from
altered protein biogenesis at the level of gene transcription, such as aberrant
splicing (1), ribosomal translation (2), folding and assembly (3) that occurs in
the endoplasmic reticulum (ER), export from the ER to the Golgi apparatus for
maturation (4) and budding from the trans-Golgi network (TGN) and sorting (5).
Once at the plasma membrane, besides intrinsic electrophysiological defects (7),
ion channels may suffer from improper compartmentalization (8), incorrect
clustering (9) or abnormalities in their recycling/degradation (10).
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#141500) is a rare autosomal dominant form of migraine with
aura, characterized by recurrent attacks of disabling headache
and in some cases, progressive cerebellar atrophy. Following the
study by Ophoff et al. [22], describing the first missense
mutations linked to FHM1, several others have since been
reported (up to 10). Although altogether suggestive of a gain of
channel activity, electrophysiological characterizations of
FHM1 mutant CaV2.1 channels in heterologous expression
systems reveal complex biophysical characteristics both in terms
of recovery from inactivation [25] and single channel gating
[26]. More compelling evidence for an increase in channel
activity of FHM1 mutant was presented by Van den Maagden-
berg et al. [27] who generated a knock-in mouse mutant bearing
the human R192Q CACNA1A mutation. Recordings from
R192Qmice cerebellar granule cells show an increase in CaV2.1
current density and a hyperpolarizing shift in the voltage-
dependence of the current activation. Importantly, the R192Q
mice show enhanced neurotransmitter release and increased
susceptibility to cortical spreading depression.
Episodic ataxia type 2 (EA2, OMIM #108500) is an
autosomal dominant paroxysmal cerebellar disorder, character-
ized by ataxia, migraine-like symptoms, interictal nystagmus
and cerebellar atrophy. In some patients, symptoms can be fully
controlled with acetazolamide, a carbonic anhydrase inhibitor.
There are now more than 20 known CACNA1A mutations
linked to EA2. Most of them are nonsense mutations [28] and a
few others are missense mutations [29,30]. Most nonsense
mutations are predicted to lead to truncated CaV2.1 proteins,
which would be incorrectly folded. An expected consequence is
that these EA2 mutant CaV2.1 proteins are unable to function as
calcium channels. Heterologous expression of truncated EA2
mutant CaV2.1 protein, together with wild type CaV2.1 protein
significantly decreases P/Q type current, which indicates that
truncated EA2 mutant CaV2.1 proteins can produce a dominant
negative effect [31]. In the latter study, a similar result is also
obtained with missense EA2 mutations. Originally the mech-
anism of EA2-mediated reduction of the P/Q-type current
density was thought to be due to either defective biosynthetic
processing or sequestering of the regulatory β subunits. An
alternative hypothesis, which now needs further evaluation, is
that misfolded EA2 mutants accumulate in the endoplasmic
reticulum (ER, see Fig. 4) and trigger an ER-mediated
translation inhibition mechanism known as the unfolded protein
response [32,33]. Such “suicide subunits” may be a hallmark of
the various P/Q-type channel defects in EA2. Jouvenceau et al.
[34] reported that generalized epilepsy can also be found
associated with EA2 and described that the primary effect of the
R1820x nonsense mutation in heterologous expression systems
is a loss of channel activity. Interestingly this mutant protein
also displays a dominant-negative effect when co-expressed
with wild-type CaV2.1.
Spinocerebellar ataxia type 6 (SCA6, OMIM #183086) is an
autosomal dominant paroxysmal cerebellar disorder character-
ized by late-onset, slow-progressive ataxia and Purkinje neuron
degeneration. SCA6 is associated with an expansion of a CAG
repeat (over 19 repeats) at the distal carboxy terminus of CaV2.1[24,35]. Electrophysiological analysis of SCA6 mutants in
heterologous expression systems provided heterogeneous
results: either a shift of the voltage-dependent inactivation
to more negative potentials, which would reduce the available
channel population at resting membrane potential [36]; or
increased current density attributable to elevated protein
expression at the cell surface [37]. In addition, Kordasiewicz
et al. [38] recently reported that a portion of the CaV2.1
carboxy-terminus is cleaved and directed to the nucleus.
While the wild-type carboxy terminal fragment is weakly
toxic, a fragment containing an expanded polyglutamine tract
corresponding to the SCA6 mutation is highly toxic to
Purkinje neurons. This study not only suggests a possible
pathogenic mechanism for SCA6 but also reveals a novel
form of P/Q-type channel processing that may play a role in
nuclear signalling.
The neuronal channelopathies linked to CACNA1A muta-
tions, migraine, ataxia and seizures present significant comor-
bidity suggesting shared pathophysiological mechanisms [21].
Indeed, many spontaneous mutations in the mouse gene cac-
na1a are also linked to cerebellar ataxia and seizures. The
systematic analysis of these mouse models has been instrumen-
tal in clarifying how different mutations affect channel function
and how altered channel function can produce disease (reviewed
in [23,39,]). Several spontaneous mutations in the mouse strains
tottering (tg), leaner (tgla), rolling Nagoya (tgrol), rocker (rkr),
lethargic (lh), ducky (du and du2j), entla (ent) and stargazer
(stg) are associated with cerebellar ataxia and seizures that
resemble generalized absence epilepsy (Table 1). The pheno-
types lethargic, ducky and stargazer are linked to mutations in
the regulatory subunits, β4, α2δ2 and γ2, respectively. The
overlapping phenotypes caused by mutations in the four
Table 1
A list of the human inherited calcium channelopathies identified to date (left
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molecular nature of functional P/Q-type calcium channels in
the cerebellum (Fig. 3B). Reminiscent of the lethargic phenotype
inmouse, which is associated with amutation in theβ4 subunit, a
seizure phenotype has been reported in a patient harbouring a
mutation in the CACNB4 gene [40].
4. Calcium channelopathies associated with T-type VGCCs
To date, of the three T-type calcium channel genes (Fig. 2),
only mutations in CACNA1H, which codes for the CaV3.2
subunit, have been identified. Chen et al. [41] found twelve
missense mutations in CACNA1H associated with childhood
absence epilepsy (CAE) and Heron et al. [42] reported three
other missense mutations linked to idiopathic generalized
epilepsy (IGE). Although an increase in T-type channel activity
has been implicated in absence epilepsy in many instances,
electrophysiological characterization of CaV3.2 CAE mutations
has failed to consistently identify a significant gain of channel
activity [43,44]. Interestingly, many of the CAE mutations are
present in the linker between domain I and II of the CaV3.2,
suggesting a functional role of this intracellular linker that has
yet to be identified.
Recently, six missense mutations linked to autism spectrum
disorder (ASD) were found within CACNA1H [45]. All these
mutations significantly reduced CaV3.2 channel activity.
Mutations in CaV3.2 channels may not be the major impairment
causing the ASD phenotype – autism being a complex,
behaviourally defined, static disorder of the immature brain –
but rather act as modifiers of the phenotypic expression.
Interestingly, it should be noted that one third of the ASD
patients suffer from epilepsy [45]. Based on the critical role ofT-type calcium channels in neuronal development and excit-
ability [46], it is reasonable to consider that mutations in T-type
channels affect proper neuronal function.
5. Calcium channelopathies… what's next?
Studies of calcium channelopathies, as for other ionic
channels (reviewed in [47]), have provided important para-
digms of (1) how calcium channel subunit interactions take
place, (2) how loss – or gain – of channel activity may occur
and (3) how dominance can arise through haploinsufficiency,
gain of function or through a dominant negative mechanism. It
now becomes clear that the large phenotypic variability linked
to mutations in calcium channel genes does not simply reflect
electrophysiology-related gain or loss of channel activities, or
more subtle variations in the biophysical parameters. Indeed,
there is growing evidence for alterations in VGCC activity that
can be attributed to defects in channel protein biosynthesis and
trafficking, as illustrated in Fig. 4. The existence of truncated
channel subunits (as in EA2 and CSNB2) has revealed that
many mutations may disrupt folding and trafficking of the pore
subunit to the cell surface [33,48]. The studies of spontaneous
mouse mutants have provided important clues to the pathogen-
esis of the corresponding human diseases. Importantly, a new
generation of mouse models matching human mutations has
been successfully developed using knock-in strategies [27],
which will undoubtedly help to elucidate in greater details the
pathogenicity of the targeted mutations and foster identification
of novel therapeutic strategies.
Phenotypes of the monogenic calcium channelopathies can
be predicted on the basis of the tissue patterns of gene
expression in many cases, especially when the phenotype is
restricted to one tissue, as for HypoPP1 and CSNB2, which are
limited to skeletal muscle and retina dysfunctions, respectively.
In contrast, mutations in CaV1.2 L-type channel that is
ubiquitously expressed, produce complex phenotypic traits,
exemplified by Timothy syndrome that includes cardiac
(LQT8), secretory (hypoglycaemia) and neuronal (autism)
disorders. As several mutations have been described only
recently, it is obvious that the list of VGCC mutations identified
in the human population will continue to expand, especially for
neurological disorders. Epilepsy is one of the most prominent
neurological disorders and there is growing evidence establish-
ing P/Q-type and T-type channels as important contributors to
seizure genesis [49], although the precise mechanistic details
remain unclear. The VGCC mutations provide exciting
molecular tools to elucidate the contribution of the various
VGCCs to normal and disease states. The ability of mutant
VGCCs to cause a wide range of monogenic diseases suggests
they are likely to be important contributors to polygenic
diseases, especially those of neurological nature. Indeed VGCC
mutations are now implicated in some complex multigenic
neuropsychiatric disorders, such as ASD [45]. Although
calcium channel genes probably reflect only a minority of the
relevant etiological candidates in polygenic disorders, they
warrant special interest as they represent convenient drug
targets for novel therapeutics.
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